Defective in cullin neddylation 1 domain-containing protein 1 (DCUN1D1), also known as SCCRO, is a critical component of the cullin-RING ligase (CRL) multi-protein complex. Operating as a co-E3 ligase, DCUN1D1 potentiates the transfer of NEDD8 to cullins, a process essential for CRL activation and subsequent ubiquitination of key regulatory proteins. Amplified and overexpressed in various squamous cell carcinomas (including lung and head and neck cancers), DCUN1D1 has emerged as a high-value oncogenic target. Modern drug discovery efforts focus on disrupting the protein-protein interaction (PPI) between DCUN1D1 and the E2 conjugating enzyme UBE2M (UBC12) or developing targeted protein degraders (PROTACs).
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DCUN1D1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DCUN1D1 Recombinant Protein (Full-Length / PONY Domain) High purity (>95%), Endotoxin controlled. Sequence Verified by Mass Spec. Tag options available (His/GST/Flag). |
View DCUN1D1 Products |
| Gene Delivery | DCUN1D1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View DCUN1D1 Products |
| Benchmark Ab | Anti-DCUN1D1 Recombinant Antibody High-affinity positive control for Western Blot, IHC, and IP validation. |
View DCUN1D1 Products |
| Validator | DCUN1D1 siRNA Set Target-specific knockdown verification in cancer cell lines. |
View DCUN1D1 Products |
| Related Target A | UBE2M (UBC12) Direct binding partner of DCUN1D1; essential for the neddylation cascade. |
View UBE2M Products |
| Related Target B | CUL1 Cullin scaffold protein neddylated via the DCUN1D1-UBE2M complex. |
View CUL1 Products |
| Related Target C | CUL3 Cullin scaffold protein involved in Nrf2 degradation, regulated by DCUN1D1. |
View CUL3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Disrupting PPI (DCUN1D1-UBE2M) | High-purity, structurally stable DCUN1D1 and UBE2M proteins optimized for TR-FRET and AlphaLISA binding assays. |
| Selectivity Screening (DCUN1D1-5) | Full panel of DCUN1D family homolog proteins (DCUN1D1 to DCUN1D5) verified by sequence and purity. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and siRNA pools included for target validation. |
| Conformation-Dependent Binding | Lentivirus-mediated overexpression tools to preserve native intracellular complex structures. |
Live DCUN1D1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the neddylation pathway has transitioned from broad-spectrum pathway inhibition (such as the NAE inhibitor Pevonedistat/MLN4924) to highly specific, gene-targeted intervention. DCUN1D1 represents a focal point in this shift. Because DCUN1D1 is selectively amplified in specific squamous cell lineages, targeting this node offers a superior therapeutic index compared to upstream pathway inhibitors. The current pipeline features a transition from academic proof-of-concept small molecules to biopharma-backed lead optimization, with dual-acting PPI inhibitors and PROTACs leading the modality race.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Academic/Biotech consortia | Squamous Cell Lung Carcinoma, HNSCC | In vitro neddylation assay (Requires active DCUN1D1, UBE2M, and CUL1/3 proteins) |
| PROTAC / Degrader | Targeted Protein Degradation specialists | Solid tumors with 3q26 amplification | Ternary complex formation assays (Requires tag-specific DCUN1D1 and E3 ligase components) |
| Combination Therapies | Oncology-focused biopharma | Platinum-resistant cancers | Synergy screening (Requires stable target knockdown via validated siRNA) |